PubRank

Francesca Lavatelli

Author PubWeight™ 24.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006 1.95
2 Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2011 1.58
3 Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007 1.48
4 Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009 1.34
5 The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2004 1.30
6 A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2012 1.10
7 Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009 1.10
8 The workings of the amyloid diseases. Ann Med 2007 1.04
9 Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 2013 0.98
10 Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2008 0.97
11 Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2011 0.95
12 Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2013 0.92
13 Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 2013 0.91
14 Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol 2011 0.83
15 Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006 0.83
16 AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009 0.83
17 A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. PLoS One 2013 0.82
18 Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 2013 0.81
19 Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012 0.80
20 Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 2011 0.80
21 Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk 2011 0.79
22 Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics Clin Appl 2013 0.78
23 Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid 2012 0.77
24 Proteomics in protein misfolding diseases. Clin Chem Lab Med 2009 0.76
25 Biochemical markers in early diagnosis and management of systemic amyloidoses. Clin Chem Lab Med 2014 0.75
26 The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clin Chem Lab Med 2016 0.75